Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
A phase 1/2 trial of RO7247669 in melanoma, non-small-cell lung cancer and oesophageal cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04140500 by Hoffmann-La Roche, with 170 participants enrolled, started 2019-11-11 and due to reach its primary completion in 2027-06-30. Interventions recorded: RO7247669.
Similar pages
not linked directly; found by shared links- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Shares Flatiron Health (Roche), Non-small-cell lung cancer and the tag pipeline.
- TrialA Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Shares Flatiron Health (Roche) and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialSafety and Efficacy of OBX-115 in Advanced Solid Tumors
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Shares Oesophageal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Shares Flatiron Health (Roche) and the tag pipeline.
- TrialA Study of IDP-001 in Advanced or Metastatic Solid Tumors
Shares Oesophageal cancer, Non-small-cell lung cancer and the tag pipeline.